RJA
OPRX icon

Raymond James & Associates’s OptimizeRx OPRX Stock Holding History

Raymond James & Associates’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,565
Closed -$317K – 4086
2022
Q2 		$317K Sell
11,565
-551
-5% -$16.3K ﹤0.01% 3195
2022
Q1 		$457K Buy
12,116
+2,111
+21% +$93.4K ﹤0.01% 3122
2021
Q4 		$621K Buy
10,005
+508
+5% +$38.5K ﹤0.01% 2929
2021
Q3 		$812K Sell
9,497
-3,540
-27% -$222K ﹤0.01% 2718
2021
Q2 		$807K Sell
13,037
-72
-0.5% -$3.66K ﹤0.01% 2734
2021
Q1 		$639K Buy
13,109
+3,085
+31% +$149K ﹤0.01% 2827
2020
Q4 		$312K Sell
10,024
-740
-7% -$18.1K ﹤0.01% 3101
2020
Q3 		$224K Buy
+10,764
New +$185K ﹤0.01% 3140

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Raymond James & Associates's OPRX Position: Q3 2022 in Review

Raymond James & Associates sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 11,565 shares — an estimated $317K sold.

Raymond James & Associates first reported a position in OPRX in Q3 2020 and held it in 8 quarters. The position peaked at $812K in Q3 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

  • Raymond James & Associates reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 11,565 OptimizeRx shares in Q3 2022, an estimated $317K.
  • Raymond James & Associates first reported a position in OptimizeRx in Q3 2020 and held it in 8 quarters.
  • Raymond James & Associates's OptimizeRx position peaked at $812K in Q3 2021.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.